P0917N-ACETYL CYSTEINE FAILS TO IMPACT ON PLASMA ANTIOXIDANT CAPACITY IN BOTH A PLACEBO CONTROLLED CROSSOVER STUDY AND A PARALLEL GROUP TRIAL OF PATIENTS WITH CKD STAGE III: IMPLICATIONS FOR ITS USE AS A PROPHYLACTIC FOR CONTRAST INDUCED NEPHROPATHY

Khuram Raja; Kirsty Hickson; Andrew Treweeke; Gordon Rushworth; Emma Morrison; Euan Sandilands; James Cobley; David McEneaney; Michael Eddleston; Ian Megson

Journal Article

P0917N-ACETYL CYSTEINE FAILS TO IMPACT ON PLASMA ANTIOXIDANT CAPACITY IN BOTH A PLACEBO CONTROLLED CROSSOVER STUDY AND A PARALLEL GROUP TRIAL OF PATIENTS WITH CKD STAGE III: IMPLICATIONS FOR ITS USE AS A PROPHYLACTIC FOR CONTRAST INDUCED NEPHROPATHY

Raja K
Hickson K
Treweeke A
et al.

Nephrology Dialysis Transplantation (2020) 35(Supplement_3)

DOI: 10.1093/ndt/gfaa142.p0917

N/ACitations

5Readers

Get full text

Abstract

This project has been funded by the EU’s INTERREG VA programme, managed by the special EU Programmes Body (SEUPB)

Cite

CITATION STYLE

APA

Raja, K., Hickson, K., Treweeke, A., Rushworth, G., Morrison, E., Sandilands, E., … Megson, I. (2020). P0917N-ACETYL CYSTEINE FAILS TO IMPACT ON PLASMA ANTIOXIDANT CAPACITY IN BOTH A PLACEBO CONTROLLED CROSSOVER STUDY AND A PARALLEL GROUP TRIAL OF PATIENTS WITH CKD STAGE III: IMPLICATIONS FOR ITS USE AS A PROPHYLACTIC FOR CONTRAST INDUCED NEPHROPATHY. Nephrology Dialysis Transplantation, 35(Supplement_3). https://doi.org/10.1093/ndt/gfaa142.p0917

P0917N-ACETYL CYSTEINE FAILS TO IMPACT ON PLASMA ANTIOXIDANT CAPACITY IN BOTH A PLACEBO CONTROLLED CROSSOVER STUDY AND A PARALLEL GROUP TRIAL OF PATIENTS WITH CKD STAGE III: IMPLICATIONS FOR ITS USE AS A PROPHYLACTIC FOR CONTRAST INDUCED NEPHROPATHY

Abstract

Cite

Register to see more suggestions